These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 12663234)

  • 1. Interim results of a pilot study demonstrating the early effects of the PPAR-gamma ligand rosiglitazone on insulin sensitivity, aminotransferases, hepatic steatosis and body weight in patients with non-alcoholic steatohepatitis.
    Neuschwander-Tetri BA; Brunt EM; Wehmeier KR; Sponseller CA; Hampton K; Bacon BR
    J Hepatol; 2003 Apr; 38(4):434-40. PubMed ID: 12663234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone.
    Neuschwander-Tetri BA; Brunt EM; Wehmeier KR; Oliver D; Bacon BR
    Hepatology; 2003 Oct; 38(4):1008-17. PubMed ID: 14512888
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis.
    Promrat K; Lutchman G; Uwaifo GI; Freedman RJ; Soza A; Heller T; Doo E; Ghany M; Premkumar A; Park Y; Liang TJ; Yanovski JA; Kleiner DE; Hoofnagle JH
    Hepatology; 2004 Jan; 39(1):188-96. PubMed ID: 14752837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial.
    Ratziu V; Giral P; Jacqueminet S; Charlotte F; Hartemann-Heurtier A; Serfaty L; Podevin P; Lacorte JM; Bernhardt C; Bruckert E; Grimaldi A; Poynard T;
    Gastroenterology; 2008 Jul; 135(1):100-10. PubMed ID: 18503774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonalcoholic steatohepatitis: histologic features and clinical correlations with 30 blinded biopsy specimens.
    Brunt EM; Neuschwander-Tetri BA; Oliver D; Wehmeier KR; Bacon BR
    Hum Pathol; 2004 Sep; 35(9):1070-82. PubMed ID: 15343508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Therapeutic effects of insulin-sensitizing drugs on nonalcoholic fatty liver disease: experiment with rats].
    Zhang DM; Zhang GY; Wang T; Zhong HJ; Chen WK
    Zhonghua Yi Xue Za Zhi; 2006 May; 86(18):1279-83. PubMed ID: 16796890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biochemical and histological characterisation of an experimental rodent model of non-alcoholic steatohepatitis - Effects of a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist and a glucagon-like peptide-1 analogue.
    Daniels SJ; Leeming DJ; Detlefsen S; Bruun MF; Hjuler ST; Henriksen K; Hein P; Karsdal MA; Brockbank S; Cruwys S
    Biomed Pharmacother; 2019 Mar; 111():926-933. PubMed ID: 30841472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical trial: insulin-sensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis.
    Idilman R; Mizrak D; Corapcioglu D; Bektas M; Doganay B; Sayki M; Coban S; Erden E; Soykan I; Emral R; Uysal AR; Ozden A
    Aliment Pharmacol Ther; 2008 Jul; 28(2):200-8. PubMed ID: 18445142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The establishment of a novel non-alcoholic steatohepatitis model accompanied with obesity and insulin resistance in mice.
    Cong WN; Tao RY; Tian JY; Liu GT; Ye F
    Life Sci; 2008 May; 82(19-20):983-90. PubMed ID: 18417155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rosiglitazone prevents nutritional fibrosis and steatohepatitis in mice.
    Nan YM; Fu N; Wu WJ; Liang BL; Wang RQ; Zhao SX; Zhao JM; Yu J
    Scand J Gastroenterol; 2009; 44(3):358-65. PubMed ID: 18991162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: a 12-month randomized, prospective, open- label trial.
    Torres DM; Jones FJ; Shaw JC; Williams CD; Ward JA; Harrison SA
    Hepatology; 2011 Nov; 54(5):1631-9. PubMed ID: 21748770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis.
    Lutchman G; Modi A; Kleiner DE; Promrat K; Heller T; Ghany M; Borg B; Loomba R; Liang TJ; Premkumar A; Hoofnagle JH
    Hepatology; 2007 Aug; 46(2):424-9. PubMed ID: 17559148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study.
    Huang MA; Greenson JK; Chao C; Anderson L; Peterman D; Jacobson J; Emick D; Lok AS; Conjeevaram HS
    Am J Gastroenterol; 2005 May; 100(5):1072-81. PubMed ID: 15842581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [An experimental study on the reverse mechanism of PPAR-gamma agonist rosiglitazone in rats with non-alcoholic steatohepatitis].
    Zhao CY; Wang YD; Zhou JY; Jia B; Cui JF
    Zhonghua Gan Zang Bing Za Zhi; 2007 Jun; 15(6):450-5. PubMed ID: 17594812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis.
    Aithal GP; Thomas JA; Kaye PV; Lawson A; Ryder SD; Spendlove I; Austin AS; Freeman JG; Morgan L; Webber J
    Gastroenterology; 2008 Oct; 135(4):1176-84. PubMed ID: 18718471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and effectiveness of rosiglitazone in type 2 diabetes patients with nonalcoholic Fatty liver disease.
    Wang CH; Leung CH; Liu SC; Chung CH
    J Formos Med Assoc; 2006 Sep; 105(9):743-52. PubMed ID: 16959622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of rosiglitazone on the liver histology and mitochondrial function in ob/ob mice.
    García-Ruiz I; Rodríguez-Juan C; Díaz-Sanjuán T; Martínez MA; Muñoz-Yagüe T; Solís-Herruzo JA
    Hepatology; 2007 Aug; 46(2):414-23. PubMed ID: 17654601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rosiglitazone attenuates liver inflammation in a rat model of nonalcoholic steatohepatitis.
    Tahan V; Eren F; Avsar E; Yavuz D; Yuksel M; Emekli E; Imeryuz N; Celikel C; Uzun H; Haklar G; Tozun N
    Dig Dis Sci; 2007 Dec; 52(12):3465-72. PubMed ID: 17436085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acetyl-L-carnitine and lipoic acid improve mitochondrial abnormalities and serum levels of liver enzymes in a mouse model of nonalcoholic fatty liver disease.
    Kathirvel E; Morgan K; French SW; Morgan TR
    Nutr Res; 2013 Nov; 33(11):932-41. PubMed ID: 24176233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pioglitazone ameliorates nonalcoholic steatohepatitis by down-regulating hepatic nuclear factor-kappa B and cyclooxygenases-2 expression in rats.
    Zhao JS; Zhu FS; Liu S; Yang CQ; Chen XM
    Chin Med J (Engl); 2012 Jul; 125(13):2316-21. PubMed ID: 22882855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.